Prothena Corporation plc Announces Pricing Of Public Offering Of 4,750,000 Ordinary Shares
6/25/2014 8:08:33 AM
DUBLIN, Ireland, June 25, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that it has priced an underwritten public offering of 4,750,000 of its ordinary shares at a price to the public of $22.50 per ordinary share, before underwriting discounts and commissions. All of the ordinary shares in the offering are to be sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 712,500 ordinary shares.
Help employers find you! Check out all the jobs and post your resume.
comments powered by